Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan
· Delayed Price · Currency is TWD 75.60
-4.40 (-5.50%)
Mar 9, 2026, 1:30 PM CST
Gongwin Biopharm Holdings Company Description
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore.
It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.
The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment.
Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co., Ltd.
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mao-Yuan Lin |
Contact Details
Address: No. 80, Jianguo North Road Taipei, 10491 Taiwan | |
| Phone | 886 2 2503 5282 |
| Website | gongwinbiopharm.com |
Stock Details
| Ticker Symbol | 6617 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG409471060 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chonghan Wu Ph.D. | Founder and Chairman |
| Mao-Yuan Lin | GM and Director |
| Chang En Wang | Assistant Manager of Marketing Division |
| Rocky Shih | Co-Founder |
| Wei Nan Hu | Chief Financial Officer and Head of Administration Division |
| Wei Nan Hu | Accounting Director |
| Quan-Qing Yang | Deputy General Manager |